GleamWall
中文EN

STTK Shattuck Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680367 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-66.6%
TTM net income YoY14.5%
TTM EPS YoY63.6%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,578.7%
Net margin-5,256.8%
FCF margin—
EBITDA margin-5,221.0%

Returns

ROE-39.2%
ROA-36.9%
ROIC (approx.)-57.1%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets4.3%
Debt / equity0.00x
Current ratio27.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.00M$5.72M
R&D expense$35.27M$67.21M
SG&A expense$17.23M$19.08M
Operating income-$51.51M-$80.57M
Income tax$0$0
Net income-$48.81M-$75.41M
EBITDA-$47.81M-$76.77M
EPS (basic)-0.70-1.49
EPS (diluted)-0.70-1.49
Weighted avg. shares (diluted)69.58M50.76M
Balance sheet
Cash & equivalents$54.19M$57.39M
Current assets$82.47M$79.22M
PP&E, net$6.11M$9.81M
Total assets$91.03M$91.05M
Current liabilities$7.05M$8.92M
Total liabilities$8.64M$11.42M
Shareholders' equity$82.39M$79.63M
Shares outstanding63.28M47.71M
Cash flow statement
Operating cash flow-$39.88M-$60.52M
Capital expenditure$71,000$59,000
Free cash flow-$39.95M-$60.57M
Investing cash flow-$7.89M-$8.51M
Financing cash flow$44.57M$787,000
Depreciation & amortization$3.70M$3.80M
Stock-based compensation$7.00M$9.55M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.